Post hoc TSC analysis links caregiver-perceived improvement to seizure…
Clinically Meaningful Reduction in Seizure Frequency in Patients with Tuberous Sclerosis Complex Treated with Cannabidiol.
AI Summary
This post hoc analysis asked how much seizure reduction caregivers considered meaningful for people with tuberous sclerosis complex (TSC) treated with cannabidiol (CBD). It examined pooled results from 132 participants who received 25 or 50 mg/kg/day of CBD in a randomized controlled trial, over 16 weeks. The analysis compared changes in seizure frequency with caregiver ratings of overall change; it was not a new trial comparing CBD with another treatment.
Caregivers’ rating of “slightly improved” or better corresponded to a 33% seizure reduction, while “much improved” or better corresponded to a 52% reduction. The authors suggest that a 50% threshold may miss some improvements caregivers regard as meaningful. This was an exploratory, post hoc analysis of caregiver reports, so it cannot establish that these thresholds apply to every person with TSC or demonstrate CBD’s treatment effect on its own.
💡 Key Findings
📄
Original Abstract
Related Research
Similar Studies
More CBD research papers you might find interesting.
Randomized trial finds CBD did not reduce severe behavioral problems
Preclinical evidence finds no stable CBD dose-response for fear
Repeated high-dose CBD in young rats was followed by mixed social changes and…
Explore More Research
Stay informed about the latest cannabis science.